10.15
+0.02(+0.20%)
Currency In USD
| Previous Close | 10.13 |
| Open | 10.15 |
| Day High | 10.15 |
| Day Low | 10.15 |
| 52-Week High | 17.63 |
| 52-Week Low | 4.8 |
| Volume | 11.01M |
| Average Volume | 1.34M |
| Market Cap | 448.68M |
| PE | -2.15 |
| EPS | -4.73 |
| Moving Average 50 Days | 10.13 |
| Moving Average 200 Days | 8.29 |
| Change | 0.02 |
Data not available
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
GlobeNewswire Inc.
Jul 21, 2025 11:29 AM GMT
WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (“iTeos”) (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (“Concentra”) wil
iTeos Therapeutics Announces Its Intention to Wind Down Operations
GlobeNewswire Inc.
May 28, 2025 12:30 PM GMT
- Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215, and a preclinical obesity program targeting EN
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
GlobeNewswire Inc.
May 13, 2025 11:55 AM GMT
– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program – iTeos has initiated a